LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data

The LIGHTSITE I data was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern. Dr. Munk was part of the investigator team.

“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05). Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. Munk.

“Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. “The PBM therapy was most beneficial in dry AMD patients immediately following the completion of the treatment sessions. Contrast sensitivity or detailed vision was significantly improved throughout the year. Retreatments at a 6 month interval were performed to maintain clinical benefits.”

Read the full press release:
LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data

Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.